



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 20<sup>TH</sup> MARCH 2019 AT  
12.00pm

IN MEETING ROOM 2, TRUST HEADQUARTERS,  
ROYAL BLACKBURN HOSPITAL

### PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr T Mackenzie (TM)	GP, EL CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

### IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
Mr H Usmani	Consultant Ophthalmologist, ELHT - item 2019/040

### 2019/036: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT

### 2019/037: DECLARATION OF INTEREST

None declared – relevant to agenda items.

### 2019/038: MINUTES OF FEBRUARY MEETING:

Accepted as a correct record.

## **2019/039: MATTERS ARISING:**

**2018/164: Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance®, Clinitas Multi®** - on main agenda item 2019/040

**2019/007: LMMG Recommendations (from Dec LMMG) - Choice of DOAC for stroke prevention in AF Position Statement** – on main agenda item 2019/044

**2019/025: ELHE: Respiratory Guidelines – Updated: COPD Guideline** NICE and GOLD have both issued updated guidance with LABA/LAMA now being the first choice treatment for many patients so guideline needs updating with respect to these changes. JV/LR to review, send for consultation and then bring back to meeting in April. KB to suggest alternative wording for the antibiotics for managing exacerbations section.

**2019/027: Antihistamines Prescribing Policy** – not being pursued, subject covered in self care policy.

## **2019/040: DRY EYE PRODUCTS REVIEW INCLUDING NEW PRODUCT REQUESTS – VISUXL® AND SYSTANE BALANCE®**

Mr Usmani, Consultant Ophthalmologist in attendance for this item.

Mr Usmani suggested that the highlighted products on the formulary summary document could be removed from formulary in line with self-care for patients with mild/moderate dry eye. The remaining products could be available for prescribing for severe dry eye which can have serious consequences if not treated. Discussion included when the dry eye was secondary to other conditions for example when using drops for glaucoma, and those requiring long term treatment, should some of the simple products still be prescribed or just those for more severe dry eye.

Sodium hyaluronate 0.2% is still required to be available, but concern expressed with the Evolve® bottle delivery of drops and Xailain HA® suggested as a possible alternative.

JV to amend the formulary summary and choices in line with discussions and bring back proposals to next meeting.

**Action: Formulary choices to be updated and come back for consideration.**

VISUXL®, crosslinked hyaluronic acid & co enzyme Q10, requested to add to formulary for patients with slow epithelial healing, for example after surgery or with non-healing ulcers, for a limited period of time. Concerns were raised over limited evidence available but Mr Usmani reported anecdotally improvements have been seen. It was agreed to add to formulary only for patients with slow epithelial healing to allow assessment of the product's effectiveness. Patients would remain under hospital specialist care and information to be collected and presented to ELMMB in future re patient outcomes. Red traffic light allocated.

SYSTANE BALANCE®, a lipid based lubricating eye drop, requested to add to formulary for patients with evaporative dry eye eg from Meibomian gland dysfunction. Concerns raised over limited available evidence. This is currently the only drop containing lipids which can help when dry eye is due to rapid evaporation, as opposed to not producing sufficient lubricant. It was agreed to add to formulary for initiation by specialists. Treatment would be expected to be long term therefore continued by GP's with Amber traffic light allocated.

**Resolved: VisXL® added to formulary for use by specialists only. Traffic Light:Red Systane Balance® added to formulary for specialist initiation. Traffic Light: Amber**

## **2019/041: LUTEIN & ORAL ANTIOXIDANT VITAMIN SUPPLEMENTS FOR EYE CONDITIONS**

A position statement to not prescribe supplements for eye conditions was discussed briefly. To be referred to ophthalmologist specialising in macular degeneration for comment.

**Action: Refer to ophthalmologist specialising in macular degeneration for comments.**

## **2019/042: WOUND CARE FORMULARY - UPDATED**

Deferred to next meeting

## **2019/043: LMMG CONSULTATIONS (for April LMMG)**

**Fortacin® (Lidocaine/Prilocaine)** for the treatment of primary premature ejaculation in adult men consultation. The proposed black traffic light recommendation was supported.

**Trans-Anal Irrigation Systems Position Statement – updated** consultation – comments included service delivery differences across Lancashire and more products have been included. Feed back to LMMG

**Resolved:** Responses sent to LMMG.

## **2019/044: LMMG RECOMMENDATIONS (from Feb LMMG)**

**Out of Area Prescribing Position Statement** – document does not cover all the circumstances required, particularly if specialist centre is located significant distances from the patient's home. Providers often use their own shared care agreements that are sent to practices requesting GPs to prescribe. ELMMB requested statement is adapted to meet the local needs.

**Action: LR/JV to adapt position statement for ELHE.**

**Choice of direct-acting oral anticoagulant (DOAC) for stroke prevention in non-valvular atrial fibrillation (AF) – updated** – this position statement not supported for ELHE.

**Denosumab Shared Care – Update** – now includes treatment of glucocorticoid-induced osteoporosis. Accepted as written for use in ELHE.

**Nebulised Colomycin® in Non-CF Bronchiectasas Prescribing Sheet (version 1.1) – update** - accepted as written for use in ELHE.

**Restless Legs Syndrome in Adults in primary Care (version 1.2) – update** – not adopted - SR has some comments to be sent to LR and LMMG.

**Action: LR to send comments to LMMG**

## **2019/045: FORMULARY UPDATES**

**VSL#3 Sachets** – to be reinstated on formulary for specialist gastroenterology use with Red traffic light as not included in drug tariff so no longer available on FP10.

**Traffic Light: Red**

**Freestyle Libre** – NHS England have issued national funding arrangements for relevant diabetes patients to reimburse CCG's for the ongoing costs based on 20% of Type 1s. Paediatric consultant has expressed concerns over arrangements for patients to receive supplies based on the LSC Policy Group red traffic light status. LR suggested it would be likely that the status would change to amber following publication of the NHSE revised criteria.

**Tranexamic acid injection for topical use** – traffic light to change to amber when recommended by specialist palliative care services.

**Traffic Light: Amber**

**Resolved: Formulary to be updated as above**

## **2019/046: LMWH BEST PRACTICE GUIDELINE – UPDATED WITH ENOXAPARIN**

ELHT has changed LMWH for prophylaxis from tinzaparin to enoxaparin due to supply issues. The guideline has been updated and is acknowledged. Implementation has gone well.

**Resolved: LMWH Best Practice Guideline update acknowledged.**

## **2019/047: PRESCRIBING FOR CLINICAL NEED POLICY**

ELMMB was not happy with the LSC LMMG Self Care Policy and suggested the NHS England policy provides a more organised, comprehensive document. LR agreed to check with LMMG that the policy circulated was the latest version.

**Action: LR to request LMMG to forward latest policy and feed back to group at next meeting.**

## **2019/048: WATERPROOF CAST COVERS**

The position statement accepted for ELHE – prescribing of waterproof cast covers is not supported.

**Resolved: Waterproof Cast Covers not supported.**

**Traffic Light BLACK**

## **2019/049: NICE RECOMMENDATIONS (from Feb)**

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) [TA560]

**Traffic Light: BLACK**

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia [TA561] is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

**Traffic Light: RED**

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562) is recommended as an option by NICE. Approved in line with NICE.  
Cancer Drugs Fund **Traffic Light: RED**

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563) is recommended as an option by NICE. Approved in line with NICE.  
Cancer Drugs Fund **Traffic Light: RED**

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564).  
**Traffic Light: BLACK**

### **2019/050: EAMS (Early Access to Medicines Scheme)**

Atezolizumab in combination with nab-paclitaxel, for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) whose tumours have PD-L1 expression  $\geq 1\%$  and who have not received prior chemotherapy for their metastatic disease – inclusion on EAMS acknowledged.

### **STANDING ITEMS**

**2019/051: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Feb 2019**  
Minutes acknowledged

**2019/052: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Jan 2019**  
Minutes acknowledged

**DATE OF NEXT MEETING – Wednesday 17<sup>th</sup> April 2019 12.00noon, Seminar Room 6, Learning & Development Centre, RBH**

Dates for 2019: All 3<sup>rd</sup> Wednesday of the month starting at 12 noon

17<sup>th</sup> April  
15<sup>th</sup> May  
19<sup>th</sup> June  
17<sup>th</sup> July  
21<sup>st</sup> August  
18<sup>th</sup> September  
16<sup>th</sup> October  
20<sup>th</sup> November  
18<sup>th</sup> December

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 20<sup>TH</sup> MARCH 2019**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/025</b>	<b>ELHE: Respiratory Guidelines – Updated COPD guideline</b> – to be updated in line with updated NICE and GOLD recommendations and KB comments	JV	Apr 19
<b>2019/040</b>	<b>Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance®</b> - formulary choices to be updated with comments and brought back for consideration.	JV	Apr 19
<b>2019/041</b>	<b>Lutein &amp; Oral Antioxidant Vitamin Supplements For Eye Conditions</b> – refer to ophthalmologist specialising in macular degeneration for comments	CW	Apr 19
<b>2019/044</b>	<b>LMMG Recommendations (from Feb LMMG) – Out of area prescribing Position Statement</b> – LR to adapt for ELHE <b>Choice of DOAC in AF</b> – send comments to LMMG <b>Restless Legs Syndrome in Primary Care</b> – send comments to LMMG	LR/JV LR LR	Apr 19 Apr 19 Apr 19
<b>2019/047</b>	<b>Prescribing For Clinical Need Policy</b> – request LMMG to send latest policy	LR	Apr 19